Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS: liposomal irinotecan + 5-fluorouracil/leucovorin + bevacizumab in second-line metastatic colorectal cancer
ChiCTR2300079257Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan, fluorouracil, folinic acid and bevacizumab in colorectal cancer (CRC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Objective response rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecanfluorouracilfolinic acidbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300079257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079257.